Literature DB >> 21849206

Persistent high factor VIII activity leading to increased thrombin generation - a prospective cohort study.

J K Ryland1, A S Lawrie, I J Mackie, S J Machin.   

Abstract

INTRODUCTION: A persistently elevated level of factor VIII (FVIII) is an independent risk factor for venous thromboembolism (VTE). Although the pathophysiology of VTE is unclear, the involvement of thrombin generation (TG) has been postulated. Consequently this study was designed to (i) investigate the relationships between FVIII, Thrombin generation test (TGT) parameters and D-dimer in VTE patients, (ii) determine whether elevated levels of FVIII and increased TG in these patients are transient or sustained. PATIENTS AND METHODS: After an initial period of anticoagulation had been completed 91 VTE patients and 52 healthy controls were recruited. FVIII levels were determined by one-stage clotting (FVIII:C) and chromogenic (FVIII:Ch) assays. The potential to generate thrombin was measured using the Calibrated Automated Thrombogram (CAT) and D-Dimer was by immuno-turbidometric assay.
RESULTS: Patients' FVIII:C levels and FVIII:Ch, exhibited good agreement (rs=0.94; p<0.0001), although FVIII:C exhibited a mean bias of -6%. FVIII:Ch show a significant correlation with TGT Peak Thrombin (rs=0.30; p=0.004) and Peak Thrombin was found to be significantly higher (p=0.04) in patients with FVIII>200 iu/dL. Furthermore elevated levels of FVIII and increased thrombin generation parameters appeared to be consistent over time.
CONCLUSION: Our data suggests that high FVIII leading to increased TG confers a significant risk of recurrent VTE and therefore we speculate that these patients may benefit from prolonged anticoagulation therapy.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21849206     DOI: 10.1016/j.thromres.2011.07.020

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

1.  Elevated factor VIII increases the risk of cerebral venous thrombosis: a case-control study.

Authors:  Loes Vecht; Susanna M Zuurbier; Joost C M Meijers; Jonathan M Coutinho
Journal:  J Neurol       Date:  2018-05-08       Impact factor: 4.849

2.  Overshoot of FVIII activity in patients with acquired hemophilia A who achieve complete remission.

Authors:  Yoshiyuki Ogawa; Kunio Yanagisawa; Chiaki Naito; Hideki Uchiumi; Takuma Ishizaki; Hiroaki Shimizu; Fumito Gohda; Masahiro Ieko; Akitada Ichinose; Hiroshi Handa
Journal:  Int J Hematol       Date:  2020-01-14       Impact factor: 2.490

Review 3.  Biomarkers of deep venous thrombosis.

Authors:  Huacheng Hou; Zhijuan Ge; Pu Ying; Jin Dai; Dongquan Shi; Zhihong Xu; Dongyang Chen; Qing Jiang
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

4.  High factor VIII, von Willebrand factor, and fibrinogen levels and risk of venous thromboembolism in blacks and whites.

Authors:  Amanda B Payne; Connie H Miller; W Craig Hooper; Cathy Lally; Harland D Austin
Journal:  Ethn Dis       Date:  2014       Impact factor: 1.847

5.  Elevated Von Willebrand Factor Antigen Levels are an Independent Risk Factor for Venous Thromboembolism: First Report from North India.

Authors:  Sweta Rajpal; Jasmina Ahluwalia; Narender Kumar; Pankaj Malhotra; Varun Uppal
Journal:  Indian J Hematol Blood Transfus       Date:  2019-02-15       Impact factor: 0.900

Review 6.  From Classical Laboratory Parameters to Novel Biomarkers for the Diagnosis of Venous Thrombosis.

Authors:  Larisa Anghel; Radu Sascău; Rodica Radu; Cristian Stătescu
Journal:  Int J Mol Sci       Date:  2020-03-11       Impact factor: 5.923

7.  Correlation between serum factor VIII:C levels and deep vein thrombosis following gynecological surgery.

Authors:  Jiayi Liu; Cuiqin Sang; Zhenyu Zhang; Ying Jiang; Shuzhen Wang; Yao Li; Xiao Shi
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

8.  Factor VIII as a potential player in cancer pathophysiology.

Authors:  Gillian E Walker; Simone Merlin; Diego Zanolini; Andrea Vandoni; Alessandro Volpe; Gianluca Gaidano; Guido Valente; Martina Olivero; Antonia Follenzi
Journal:  J Thromb Haemost       Date:  2022-01-11       Impact factor: 16.036

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.